DE602005017636D1 - Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen - Google Patents

Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen

Info

Publication number
DE602005017636D1
DE602005017636D1 DE602005017636T DE602005017636T DE602005017636D1 DE 602005017636 D1 DE602005017636 D1 DE 602005017636D1 DE 602005017636 T DE602005017636 T DE 602005017636T DE 602005017636 T DE602005017636 T DE 602005017636T DE 602005017636 D1 DE602005017636 D1 DE 602005017636D1
Authority
DE
Germany
Prior art keywords
hydantine
derivatives
treatment
new
respiratory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005017636T
Other languages
English (en)
Inventor
Balint Gabos
Lena Ripa
Kristina Stenvall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602005017636D1 publication Critical patent/DE602005017636D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602005017636T 2004-07-05 2005-07-04 Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen Active DE602005017636D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401762A SE0401762D0 (sv) 2004-07-05 2004-07-05 Novel compounds
PCT/SE2005/001092 WO2006004532A1 (en) 2004-07-05 2005-07-04 Novel hydantoin derivatives for the treatment of obstructive airway diseases

Publications (1)

Publication Number Publication Date
DE602005017636D1 true DE602005017636D1 (de) 2009-12-24

Family

ID=32768773

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017636T Active DE602005017636D1 (de) 2004-07-05 2005-07-04 Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen

Country Status (33)

Country Link
US (1) US7989620B2 (de)
EP (1) EP1778673B1 (de)
JP (1) JP4390833B2 (de)
KR (1) KR101222736B1 (de)
CN (1) CN100543024C (de)
AR (1) AR049578A1 (de)
AT (1) ATE448219T1 (de)
AU (1) AU2005260142B2 (de)
BR (1) BRPI0512974A (de)
CA (1) CA2569716C (de)
CY (1) CY1109728T1 (de)
DE (1) DE602005017636D1 (de)
DK (1) DK1778673T3 (de)
ES (1) ES2335424T3 (de)
HK (1) HK1102814A1 (de)
HR (1) HRP20100020T1 (de)
IL (1) IL179906A (de)
MX (1) MXPA06014661A (de)
MY (1) MY145613A (de)
NO (1) NO20070576L (de)
NZ (1) NZ552101A (de)
PL (1) PL1778673T3 (de)
PT (1) PT1778673E (de)
RS (1) RS51280B (de)
RU (1) RU2386629C2 (de)
SA (1) SA05260192B1 (de)
SE (1) SE0401762D0 (de)
SI (1) SI1778673T1 (de)
TW (1) TWI353985B (de)
UA (1) UA86977C2 (de)
UY (1) UY29002A1 (de)
WO (1) WO2006004532A1 (de)
ZA (1) ZA200610698B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
EP2907512A1 (de) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Hemmer von MMP-12 als antivirale Wirkstoffe
RU2555341C1 (ru) * 2014-04-29 2015-07-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ профилактики развития у детей старше 5 лет неконтролируемых форм бронхиальной астмы, обусловленных воздействием марганца и ванадия
US10420341B2 (en) 2015-01-30 2019-09-24 Basf Se Herbicidal phenylpyrimidines
EA201990335A1 (ru) 2016-07-25 2019-07-31 Басф Се Гербицидные пиримидиновые соединения
US11180470B2 (en) 2016-07-25 2021-11-23 Basf Se Herbicidal pyrimidine compounds
US20200146289A1 (en) 2017-06-14 2020-05-14 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
CA3104246A1 (en) 2018-07-16 2020-01-23 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
PL3853219T3 (pl) 2018-09-19 2023-12-18 Bayer Aktiengesellschaft Herbicydowo działające podstawione fenylopirymidynohydrazydy
CN116033902A (zh) 2020-06-26 2023-04-28 伯明翰大学 治疗脊髓损伤或相关神经组织损伤的方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) * 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) * 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (de) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoinderivat als Metalloproteaseinhibitor
JPH09505310A (ja) 1993-11-16 1997-05-27 メルク エンド カンパニー インコーポレーテッド ピペリジンショウノウスルホニルオキシトシン拮抗剤
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
JP2000500482A (ja) * 1995-11-22 2000-01-18 ダーウィン・ディスカバリー・リミテッド イミダゾール置換基を有するメルカプトアルキルペプチジル化合物並びにマトリックス金属プロテイナーゼ（ｍｍｐ）および／または腫瘍壊死因子（ｔｎｆ）のインヒビターとしての該化合物の使用
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
CA2268418A1 (en) * 1996-10-22 1998-04-30 Pharmacia & Upjohn Company .alpha.-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
EP0983239A1 (de) * 1997-05-06 2000-03-08 Novo Nordisk A/S Neue heterocyclische verbindungen
DE59802394D1 (de) * 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
CA2294171C (en) 1997-07-31 2005-10-18 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
BR9814147A (pt) 1997-11-12 2000-10-03 Darwin Discovery Ltd "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf"
IL137465A0 (en) 1998-02-04 2001-07-24 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1077974A1 (de) 1998-05-14 2001-02-28 Du Pont Pharmaceuticals Company Substituierte aryl hydroxamsäure als metalloproteinase inhibitoren
JP2002516904A (ja) * 1998-06-03 2002-06-11 ジーピーアイ ニル ホールディングス インコーポレイテッド Ｎ−複素環式カルボン酸またはカルボン酸等配電子体のｎ−結合スルホンアミド
US6429213B1 (en) * 1998-06-17 2002-08-06 Bristol Myers Squibb Pharma Co Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
JP2002526370A (ja) 1998-10-07 2002-08-20 矢崎総業株式会社 多孔質型を用いたゾル・ゲル法
PT1004578E (pt) * 1998-11-05 2004-06-30 Pfizer Prod Inc Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
KR100440643B1 (ko) 1999-01-28 2004-07-21 쥬가이 세이야쿠 가부시키가이샤 치환 페네틸아민 유도체
US20020006920A1 (en) * 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
PT1078923E (pt) * 1999-08-02 2006-07-31 Hoffmann La Roche Processo para a preparacao de derivados de benzotiofeno
KR20020060160A (ko) * 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
US6283379B1 (en) * 2000-02-14 2001-09-04 Kic Thermal Profiling Method for correlating processor and part temperatures using an air temperature sensor for a conveyorized thermal processor
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) * 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
EP1191024A1 (de) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazine und ihre Verwendung als Metallproteinaseinhibotoren
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
HUP0400206A3 (en) * 2001-03-15 2004-10-28 Astrazeneca Ab Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
EP1397137B1 (de) * 2001-05-25 2009-10-14 Bristol-Myers Squibb Company Hydantion-derivate als hemmer von matrix-metalloproteinasen
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
EP1550725A4 (de) 2002-06-05 2010-08-25 Kaneka Corp Verfahren zur herstellung eines optisch aktiven a-methylcystein-derivats
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US20040266832A1 (en) * 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
JP4390833B2 (ja) 2009-12-24
SI1778673T1 (sl) 2010-02-26
SE0401762D0 (sv) 2004-07-05
PL1778673T3 (pl) 2010-03-31
UY29002A1 (es) 2006-02-24
ZA200610698B (en) 2008-06-25
CA2569716A1 (en) 2006-01-12
JP2008505171A (ja) 2008-02-21
IL179906A (en) 2011-11-30
HK1102814A1 (en) 2007-12-07
EP1778673B1 (de) 2009-11-11
MY145613A (en) 2012-03-15
AR049578A1 (es) 2006-08-16
TWI353985B (en) 2011-12-11
NZ552101A (en) 2010-11-26
CY1109728T1 (el) 2014-09-10
SA05260192B1 (ar) 2009-02-07
RS51280B (sr) 2010-12-31
US20100144771A1 (en) 2010-06-10
NO20070576L (no) 2007-04-10
AU2005260142A1 (en) 2006-01-12
HRP20100020T1 (hr) 2010-02-28
ES2335424T3 (es) 2010-03-26
EP1778673A1 (de) 2007-05-02
RU2007101236A (ru) 2008-08-10
TW200616995A (en) 2006-06-01
CN1980914A (zh) 2007-06-13
KR20070041495A (ko) 2007-04-18
BRPI0512974A (pt) 2008-04-22
CN100543024C (zh) 2009-09-23
IL179906A0 (en) 2007-05-15
DK1778673T3 (da) 2010-03-01
CA2569716C (en) 2013-02-19
PT1778673E (pt) 2010-01-13
UA86977C2 (ru) 2009-06-10
ATE448219T1 (de) 2009-11-15
WO2006004532A1 (en) 2006-01-12
MXPA06014661A (es) 2007-02-12
AU2005260142B2 (en) 2008-08-28
US7989620B2 (en) 2011-08-02
RU2386629C2 (ru) 2010-04-20
KR101222736B1 (ko) 2013-01-15

Similar Documents

Publication Publication Date Title
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
HK1171736A1 (en) Substituted acids for the treatment of respiratory diseases
ATE430569T1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE557022T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ATE517877T1 (de) Neue arzneimittel zur behandlung von atemwegserkrankungen
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition